KRON News and Press, Kronos Bio Inc.

2024-06-05 18:25:03 ET Summary Updated data from the ongoing ph2 study of KB-0742 were disappointing, with only a single partial response. Although adverse effects are "manageable" the safety profile is far from ideal. Nevertheless, a high and durable disease control rate was repo...

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate i...

2024-05-21 08:24:08 ET More on Kronos Bio Kronos Bio: Underestimated Drug Discovery Platform Kronos cuts 21% of workforce, extends cash runway into 2H 2026 Read the full article on Seeking Alpha For further details see: Kronos Bio appoints Knobelman as CF...

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobel...

2024-05-10 07:27:16 ET More on Kronos Bio Kronos Bio: Underestimated Drug Discovery Platform Kronos cuts 21% of workforce, extends cash runway into 2H 2026 Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bio Finan...

— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 —...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-06 18:40:11 ET Summary Kronos Bio, Inc.'s drug discovery platform has a lot of potential in targeting transcription regulatory networks. Genetech collaboration validates big pharma interest. KB-0742, Kronos Bio's lead asset, is an orally bioavailable highly selective CDK9 ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory t...

2024-03-21 13:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kronos Bio (NASDAQ: KRON ) just reported results for the fourth quarter of 2023. Kronos Bio reported earnings per share of -43 cents. This was above the analyst estimate f...